A Prospective Cohort Study on Warfarin Personalized Medication
NCT06428110 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 272
Last updated 2024-05-29
Summary
Analyze the impact of the degree of blood vessel aging on the anticoagulant effect and bleeding risk of warfarin. Evaluating the possibility of using the degree of blood vessel aging to guide individualized use of the anticoagulant drug warfarin.
Conditions
- Warfarin Sodium Causing Adverse Effects in Therapeutic Use
Interventions
- OTHER
-
Sponsors & Collaborators
-
Haobin Li
lead OTHER
Principal Investigators
-
Guangchun Sun · The Fifth People's Hospital of Shanghai
Eligibility
- Min Age
- 65 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-01-01
- Primary Completion
- 2023-12-12
- Completion
- 2023-12-12
Countries
- China
Study Locations
More Related Trials
-
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
NCT06194617 ·Status: RECRUITING
-
Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study
NCT03292666 ·Status: COMPLETED
-
The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients
NCT02646267 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation
NCT03666962 ·Status: UNKNOWN
-
Genotype-guided Warfarin Individualized Treatment
NCT02211326 ·Status: COMPLETED ·Phase: NA
-
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
NCT00247702 ·Status: UNKNOWN ·Phase: NA
-
Genotype-guided Versus Standard for Warfarin Dosing
NCT03479684 ·Status: COMPLETED ·Phase: NA
-
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
NCT00005684 ·Status: COMPLETED
-
Warfarin - How Good Are we at Maintaining Target Range ?
NCT01081327 ·Status: COMPLETED
-
The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism
NCT03185845 ·Status: UNKNOWN ·Phase: NA
-
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
NCT03926780 ·Status: COMPLETED ·Phase: PHASE3
-
The DARE Warfarin CER Study
NCT03271450 ·Status: UNKNOWN
-
Study of Genetic Factors Other Than CYP2C9 and VKORC1 That Influence Warfarin Dose Requirements in a South-east Asian Population
NCT01050920 ·Status: UNKNOWN
-
Pharmacogenetic Dosing of Warfarin
NCT02065388 ·Status: COMPLETED ·Phase: PHASE3
-
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
NCT04066764 ·Status: RECRUITING ·Phase: PHASE3
-
Precision Medicine Platform for Novel Oral Anticoagulants
NCT04056143 ·Status: UNKNOWN
-
Assessment of 2012 Bioequivalence Standards for Warfarin
NCT02574754 ·Status: COMPLETED ·Phase: PHASE1
-
Effectiveness of NextDose for Warfarin Dose Individualization
NCT04510805 ·Status: UNKNOWN ·Phase: PHASE4
-
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
NCT00365950 ·Status: COMPLETED ·Phase: PHASE4
-
Anticoagulation Therapy in the Very Old
NCT03103763 ·Status: COMPLETED
-
DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation
NCT00806624 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
NCT00680186 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
NCT06947707 ·Status: RECRUITING
-
Pharmacogenetic Study of Warfarin Dose-Response: a Prospective Trial
NCT00654823 ·Status: UNKNOWN
-
Personalized Anticoagulant Therapy for Pulmonary Thromboembolism
NCT06341231 ·Status: RECRUITING